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1 Introduction 
Proteins from new or alternative sources could strongly improve the sustainability of food protein 
supply. This can be achieved via different ways, e.g. through development of new protein 
sources, improvement of crops, by providing solutions to technical challenges during 
manufacturing, by providing new nutritional sources, as well as by valorising unused side 
products. The EU General Food Law requires that consumers have access to safe and 
wholesome food of the highest standard (Regulation EC no 178/2002). Before introducing new 
or modified foods or food ingredients into the market, safety assessments must be performed to 
determine that the new product will not result in harm to the consumer and to protect public 
health. Food allergy is a relatively frequent disease in humans and, when it occurs, dietary 
proteins are usually the major contributor for the development and elicitation of allergic 
reactions.  
Methodologies and principles of risk assessment in food safety have developed and become 
harmonized to a large extent worldwide over the past half century. The risks addressed are 
mainly those posed by chemical, microbiological and physical hazards. Food allergy was a 
latecomer to the field of food safety hazards and real progress in the development of methods 
ensuring consumer protection is of rather recent date. In the first decade of this century, 
knowledge has accumulated on the sensitivity of food allergic individuals from observed 
thresholds during clinical food challenges, leading to the development of methods for assessing 
the risk to food allergic consumers from oral exposure to known allergenic food proteins already 
present in the diet (Kruizinga et al., 2008; Spanjersberg et al., 2010; Spanjersberg et al., 2007). 
Quantitative risk assessment methodologies are now available for assessing risks regarding the 
unintentional consumption of regulated (EC 1169/2011) major food allergens (Crevel et al., 
2014; Remington et al., 2015). Similar methods may also be applied to assessing potential risks 
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due to cross-reactivity between new or modified proteins and known allergens in persons with 
manifest food allergies (Verhoeckx et al., 2016). However, new or modified proteins can also 
pose a risk of de novo sensitization leading to the development of new food allergies 
This paper aims to discuss how current methodology can identify potential risks to consumer 
health from de novo IgE mediated sensitization or from a potential clinical manifestation of 
allergy provoked by new or modified food proteins. These include foods derived from genetic 
modifications or DNA recombinant technology (GMs), and Novel Foods as regulated in Europe 
by EC 1829/2003, complemented with EC 503/2013, and by EC 2015/2283, replacing the 
original EC 258/97, respectively. We discuss how existing model systems, assays and other 
methodologies contribute to the risk analysis process. The focus is on IgE mediated allergy. 
2 Allergenicity Risk Assessment 
Risk is defined as a function of the probability of an adverse health effect and the severity of that 
effect, consequential to a hazard(s) in food (CODEX, 2013). For the purposes of the current 
discussion, the hazard is the potential of a material to induce an IgE-mediated immune 
response (to be an allergen) with the adverse health outcome manifested as sensitization or as 
development of a clinical allergy. There are two phases in food allergy - the induction 
(sensitization) phase and the effector (elicitation) phase , for which separate risk assessments 
might be applicable. Assessment in the elicitation phase will mainly address the probability of 
eliciting an allergic (cross-) reaction and the severity of that reaction upon exposure to a defined 
amount of allergenic protein. The sensitization phase consists of priming the immune system, 
leading to the formation of specific IgE antibodies. The presence of IgE antibodies is a 
prerequisite, but is not the only requirement for the development of clinical allergy. There is no 
clear relationship between the intensity and degree of sensitization and its progression into 
clinical allergy. The probability of induction of sensitization is therefore higher than the risk of 
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development of allergy. Taking sensitization as the hazard metric will inevitably make the 
assessment more conservative, and over-protective than choosing the development of allergy. 
 
Most model systems and assays developed with the aim of investigating the allergenicity of new 
or modified food proteins focus on hazard assessment. They were mostly developed based on 
the characteristics of known allergens. It is unknown if these methodologies would also be 
predictive for completely new proteins or foods which have not previously been encountered.  
 
By definition, the risk due to an identified hazard depends on the quantity of the hazard needed 
to cause adverse effects and on the actual level and/or pattern of exposure to that hazard. 
Although the impact of exposure for the elicitation phase has been explored and methods for 
quantitative risk assessment for known allergens have been developed, knowledge on how 
exposure influences the development of the sensitization phase is limited. In theory, all foods or 
proteins newly introduced into the food chain can cause de novo sensitization (Houben et al., 
2016). Hazard is the intrinsic property and potency to induce de novo sensitization, modulated 
by the genetic disposition of the consuming individual. Exposure depends on many variables 
including: the amount consumed, the frequency and pattern of consumption, the concentration 
and stability of the protein in the food, co-exposure to adjuvants and the matrix when prepared 
to be consumed. For example, the expression levels of proteins currently introduced into GM-
crops for e.g. pesticide resistance are typically very low, and once incorporated into food 
products their presence, and hence exposure, is practically negligible. Such low exposure, 
together with an absence of measurable allergenic potential presents a very low risk of 
allergenicity from such commercialized GM crops. 
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For protein sources intended for nutritional purposes, the quantities ingested will be much more 
significant. There are examples where the introduction of a new or novel proteinaceous food 
into the food chain has been reported (however rarely) to cause allergic reactions. Hoff et al. 
(2003) described an asthmatic patient who experienced an allergic reaction to quorn, a brand 
name for foods containing mycoprotein from the mold Fusarium venenatum. This was confirmed 
by double-blind placebo-controlled oral challenge and the authors concluded that this was not 
due to a primary sensitization, but due to cross-reactivity with aero-allergens. Lupin was 
introduced into the food chain in the late nineties in the EU (Peeters et al., 2007). According to 
Hieta et al. (2009), allergic reactions to lupin occured most frequently among patients with other 
food allergies, mainly to legumes, indicating that lupin allergy occurs largely due to cross-
reactivity. However, others showed that lupin allergy is not always due to cross-reactivity, but 
can be the result of primary sensitization through oral exposure (Lindvik et al., 2008; Peeters et 
al., 2007), and also by prior inhalation of lupin flour (Prieto et al., 2010). Similar to lupin, kiwi fruit 
was introduced to the EU in the 20th century and soon after kiwi allergy was first reported (Fine, 
1981). Upon further investigation, kiwi allergy can result from cross-reactivity with pollen and 
latex (Diaz-Perales et al., 1999; Gall et al., 1994) or through primary sensitization (Aleman et al., 
2004).  
As discussed above, exposure to a protein may result in de novo sensitization or allergy, or 
allergic reactions through cross-reactivity. Definition of the relevant risk: e.g. the probability of 
sensitization, the probability of allergy development, the risk of allergic reactions in the allergic 
and in the general population, etc., will be crucial when developing future methodologies and 
guidance.  
 
3 Current Guidance  
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Expert scientific bodies have produced guidance for allergenicity assessment of new proteins 
and food sources that are introduced into the human diet (CODEX, 2003, 2009; EFSA, 2010, 
2011; FAO/WHO, 2001). Table 1 summarises data requirements. Key guidance documents on 
how to assess potential allergenicity were first drawn up to address proteins introduced using 
recombinant DNA (GM-)techniques (CODEX, 2003), which can be considered as the basic 
standard, with amended improvements as suggested by the advancement of scientific 
knowledge and methodologies. As no single property is recognized as predicting food allergy in 
humans, all documents recommend a weight of evidence approach. This approach takes into 
account various elements and observations judged to be important to the potential of a protein 
to cause an allergic reaction, and focusses on knowledge gained from the investigation of 
known food allergens. Common key elements in all published guidance are sequence 
homology, susceptibility to enzymatic degradation by digestive enzymes (pepsin), and specific 
IgE binding. For particular situations, further data, including in vivo studies (e.g. human), might 
be considered. The endpoint of the assessment is a conclusion about the likelihood of the GM-
derived protein being an allergen (CODEX, 2003). This approach is also applicable to the 
assessment of added food enzymes (EFSA, 2014).  
The approaches developed for GM foods have also been used to assess the potential of new 
non-GM proteins or protein-enriched food products introduced onto the market for their potential 
to cause allergic reactions (Meredith, 2005; Poulsen, 2004; Putten et al., 2011) (see examples 
in the Annex). In the EU, the scientific guidance documents for GM foods have formally evolved 
through EFSA, and only recently has a separate EFSA panel developed specific guidance for 
non-GM novel foods. Improved coordination both within and between national and international 
agencies is needed to advance future assessments. Potential allergenicity of GM-expressed 
proteins is initially assessed by amino acid sequence comparisons to known allergens, which 
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may trigger further investigation. This approach can also be applied to single, defined non-GM 
proteins, although may be less appropriate for complex novel non-GM foods because there is 
no specific transgene product to compare. If the novel food is unrelated to any other species 
containing known major allergenic proteins or is a complex food mix from a little-known source 
an investigation into the phylogenetic relationship with characterised food commodities could 
inform about the necessity for any further work. 
Three examples of novel ingredients evaluated by EFSA under the Novel Foods Regulation 
258/97/EC (European Commission, 1997) demonstrate a lack of consistency in the criteria 
applied for allergenicity assessment (Annex 1). Briefly, the use of ‘Ice Structuring Protein (ISP) 
type III HPLC12 preparation´ as food ingredient was deemed to be safe after extensive 
investigation, including a human oral immunogenicity study, as the protein was originally 
isolated from ocean pout. Fish belong to the regulated major allergens (EFSA, 2008). Rapeseed 
protein isolate was assessed as “safe under the proposed conditions of use” and approved 
despite the conclusion that a risk of sensitization to rapeseed, as well as the risk of cross-
reactivity in subjects allergic to mustard, cannot be excluded. Interestingly, the Opinion does not 
discuss the potential public health impact of the introduction of a new allergenic substance into 
the diet. Rapeseed protein as a novel food ingredient was authorised to be placed on the 
market (L 196/27) (EFSA, 2013) provided that the labelling of foods containing the ingredient is 
devised in such a way that people with mustard allergy are able to avoid consumption of those 
foods. In 2005, EFSA rejected a dossier on the use of chia as a food ingredient with the 
justification that it, among other things, lacked information with regard to the potential 
allergenicity of chia (seeds and ground). In 2009, the dossier was resubmitted containing an 
additional bibliographic search for cases of allergy to chia. This was deemed sufficient to 
approve the chia seeds with no restrictions for potential allergenicity (EFSA, 2009). These three 
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examples highlight that a more harmonised guidance on allergenicity assessment of protein-
containing novel foods (proteins, protein isolates, or protein-rich foods) is needed, as well as 
greater clarity on the criteria used by the Authority to reach its conclusions.  
 
4 Background Information: history of (safe) use 
Consideration of the ‘history of use’ (Constable et al., 2007) of a protein source, or a traditional 
food, is useful to provide important background information on how to develop a strategy for 
assessing the potential to elicit an allergic reaction, and to provide clues for optimal risk 
management. A history of safe use describes the existing safety profile including any known 
health effects, patterns of use, processing properties and protein characteristics. Similarly, the 
first step to estimate the potential of a single protein to cause an allergic reaction is to consider 
its origin, extent and mode of previous exposure and to assess the familiarity of its use. For a 
protein introduced into a GM crop, an understanding of the potential allergenic profile of the 
donor organism from which the gene is derived can provide guidance for further investigations, 
although for all practical purposes, proteins from sources with known IgE mediated allergy are 
unlikely to be considered to be brought forward into the market place.  
Importantly, this knowledge (see Table 2) cannot determine if a novel protein has the potential 
for de novo sensitization via ingestion, unless allergy has been demonstrated under other 
circumstances (e.g. inhalation). It can however be used as a starting point and indication if there 
is a possibility of cross-reactivity. 
5 Protein-centred investigations 
5.1 Bioinformatics approaches 
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Based on the current guidelines, a novel protein can be considered as a putative allergen if it 
shares greater than 35% sequence identity with a known allergen over a sliding window of at 
least 80 amino acids (CODEX, 2009). There is however little solid scientific basis for a general 
application of this rule, which has not been formally validated, as far as we know. The 
conservatism of the greater than 35% identity over 80 amino acids approaches and applicability 
to all protein families has been questioned (Herman et al., 2015; Silvanovich et al., 2009a). The 
80 amino acid sliding window approach is thought to be selected to correspond to the typical 
size of a protein domain containing IgE epitopes (Herman et al., 2009). The threshold of 35% 
was intended to identify proteins that share similar functions, since many common plant 
allergens fall within a few functional categories (Taylor, 2002). However, the 35% threshold is 
considered as conservative, as cross-reactivity usually requires more than 50-70% identity in 
the antibody-binding region of interest (Aalberse, 2000). Two of the most widely used tools for 
sequence alignment are FASTA (Pearson and Lipman, 1988) and BLAST (Altschul et al., 1990) 
that use certain weighting parameters to assess the significance of sequence alignments 
(Ladics et al., 2011). The E-score (FASTA) and E-value (BLAST) represent the probability that 
the alignment might occur by chance. The calculation of E-score incorporates parameters such 
as amino acid identity (i.e., extent to which two amino acids are invariant), amino acid similarity 
(i.e., the extent to which different amino acids may share biophysical features, such as 
molecular charge state), gaps in the alignment, length of the alignment, scoring matrix (which 
applies scoring values for aligning two amino acids together), and size of the database. It should 
be noted that the developers of the FASTA software tool provide specific guidance on their 
intended and correct usage of the software. Pearson (2016) states “In evaluating the search 
results, the expectation or E- value is the most reliable and sensitive indicator of likely sequence 
homology. For protein:protein alignments, if the E-value is less than 10−6, the sequences are 
almost certainly homologous.” Alignment of the whole sequence of the novel protein and 
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allergens in the database, without the restriction of the length of the sliding window has been 
proposed as a relevant alternative approach (Herman et al., 2015; Silvanovich et al., 2009b). 
However, although the literature referenced above suggests a greater scientific basis for E-
score than for the greater than 35% identity/80 AA sliding window (Herman et al., 2015; 
Silvanovich et al., 2009b), more detailed studies concerning the relevance of using E-score (E-
value) for predicting allergenic cross-reactivity would be of benefit. One possibility would be 
hypothesis-driven investigations with relevant human serum samples.  
A full and detailed in silico search for allergen IgE cross-reactivity requires a comprehensive, 
well-curated allergen database. The allergen database most often used currently in the 
assessment of novel proteins is the Allergen Online database from the Food Allergy Research 
and Resource Program (FARRP; www.allergenonline.org). It is updated annually and curated 
based on predefined criteria (Goodman et al., 2016). On the same concept, a new database 
called COMPARE is being built by the Health and Environment Science Institute (HESI) and 
aims to be a publicly accessible and transparent resource of allergens (HESI, 2016). Other 
allergen repositories exist, with large variability in the number of allergens listed and the 
information available (Gendel, 2009; Schein et al., 2007), e.g. Allergome, IUIS. Interestingly, 
some of them contain information or links to information on 3D structure or structural domains 
on the allergen (e.g. the Allergen Database for Food Safety, http://allergen.nihs.go.jp/ADFS/), 
whereas others include identified IgE-epitopes and/or functional motifs (e.g. the Structural 
Database of Allergenic Proteins, SDAP; http://fermi.utmb.edu/SDAP/sdap_ver.html). Other 
databases, such as AllFam, classify allergens into protein families 
(http://www.meduniwien.ac.at/allfam/). Unfortunately, not all of these online databases are 
regularly updated. In addition, the data are generally not in a detailed format that is easy to 
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incorporate with other databases/methods (Ivanciuc et al., 2011). Moreover, information 
regarding 3D structure and IgE-epitopes is limited for a large number of allergens. 
Beyond these approaches based on the Codex Alimentarius guidelines (CODEX, 2009), several 
other methods for cross-reactivity prediction exist. These include alignment-free methods based 
on the main physicochemical properties of proteins (Dimitrov et al., 2014), detection based on 
filtered length-adjusted allergen peptides (Martinez Barrio et al., 2007), pairwise sequence 
similarity vectorization (Muh et al., 2009) or amino acid and dipeptide composition of proteins 
(Saha and Raghava, 2006) . EFSA recommends to quantify sensitivity and specificity to 
evaluate the performance of bioinformatics methods (EFSA, 2010). However, such performance 
assessments require at least clear definitions of positives and negatives, applicable to all 
methods. The available bioinformatics approaches have different methodologies, use diverse 
positive and negative sets of control proteins and have widely varying validation procedures due 
to the lack of conventional criteria for non-allergenic proteins. All these factors hinder the 
performance evaluation and efficiency comparison of the existing bioinformatics approaches 
and the development of more accurate methods for allergenicity prediction. However, one of the 
fundamental problems is that there are currently no defined structural characteristics 
distinguishing allergens from non-allergens.  
In conclusion, existing bioinformatics approaches can aid to identify potential cross-reactivity of 
a protein new to the diet with known allergens. When a significant primary sequence alignment 
is obtained in silico, it is interpreted as a possibility that the novel protein could be recognized by 
IgE in consumers with the corresponding allergy. In this case, the next step in the allergenicity 
assessment requires the in vitro testing of the novel protein with patient serum for verification of 
the cross-reactivity. In practice, it is more likely that the protein will not be used in a 
commercialized product. 
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The current approaches take into account only potential similarities of the introduced protein 
with known allergens regarding the primary structures, but not the conformational epitopes. 
Investigations to identify allergenic 3D motifs and development of algorithms for structure 
prediction and comparison (e.g.Iterative Threading Assembly Refinement (I-TASSER; 
http://zhanglab.ccmb.med.umich.edu/I-TASSER/) ) is needed to understand if such information 
would be relevant to predict IgE cross reactivity. 
In the context of this present discussion, a major limitation of the current in silico methods is that 
they cannot predict de novo sensitization and cannot differentiate between sensitization and 
elicitation of allergy. Progress will require methods that exploit an understanding of the 
molecular mechanisms of allergy to define adverse outcome pathways (AOP). Once knowledge 
about the routes of entry, the pathways to antigen-presenting cells, the mechanisms of allergen 
presentation and recognition by T and B cells is improved, it could be used to facilitate the 
search for peptide fragments that characterise novel proteins with de novo sensitizing and/or 
allergenic potential.  
5.2  Enzymatic degradation assays 
The evaluation of the resistance of recombinant proteins to degradation by digestive enzymes is 
a key part of the current allergenicity assessment of GM crops (CODEX, 2009; EFSA, 2011; 
Goodman et al., 2008a). This test is based on the postulate and preliminary observations that 
resistance to gastric digestion differed between two sets of proteins derived from foods: 
commonly allergenic and rarely allergenic (Astwood et al., 1996). Thus such resistance might be 
an intrinsic feature of allergens and therefore, a new protein that is resistant to gastric digestion 
(or is partially degraded into stable fragments of sufficient size) has the potential to interact with 
the immune system, whilst a protein that is rapidly and completely degraded is unlikely to 
interact and evoke an immune response. Degradation of the protein will likely influence the 
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effective dose and severity of reaction in the elicitation phases. However, for sensitization 
purposes, the issue is rather what type of immune response is triggered by a specific protein, 
and how that is influenced by enzymatic degradation. Tolerance is also an active immune 
response, and requires the protein to interact with the immune system. Local mucosal IgA and 
IgG responses to food proteins are common. For sensitization, avoidance of interaction with the 
immune system may not be one of the most important criteria, but rather what would trigger a 
class shift and a more systemic immune response. In fact, hypotheses have been proposed 
stating that the intrinsic feature of allergens is not the resistance to digestion in the 
gastrointestinal tract, but rather the resistance to degradation within antigen-presenting cells 
(Foster et al., 2013), producing stable degradation fragments that constitute T-cell binding 
epitopes (Toda et al., 2011). Further investigation is needed to determine a correlation between 
allergenicity and susceptibility to endosomal degradation. 
Enzymatic degradation tests evaluate the susceptibility of purified proteins to degradation in 
simple pepsin resistance assays or the more sophisticated simulated gastric and/or intestinal 
fluid assays, according to a standardized protocol. In the simulated gastric fluid (SGF) test 
(Thomas et al., 2004a), the protein is incubated in the presence of pepsin (10 units/µg of 
protein) at pH 1.2 at 37° C for between 0.5 and 60 minutes. The simulated intestinal fluid (SIF) 
test differs from the SGF test in that that the pH is close to neutral (7.5) and the digestion is 
mediated by pancreatin (a mixture of duodenal enzymes). In both tests, the degradation of the 
protein and potential appearance of digestion fragments are usually evaluated by SDS-PAGE 
after various incubation times. Depending on experimental design and the question to be 
answered, it is possible to use Western blots (immunoblots), chromatography methods, e.g. 
FPLC, HPLC, or mass spectrometry, for more detailed examination of the fragments. Goodman 
et al. (2008b) proposed to classify a protein as rapidly degraded if >90% is degraded in less 
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than 2 minutes, and as stable if it is still detectable by a validated method after 60 minutes of 
incubation. Additionally, in silico tools such as PeptideCutter 
(http://web.expasy.org/peptide_cutter/) are available to predict enzymatic degradation of a 
protein before conducting laboratory experiments.  
It is crucial to understand what can be expected of these models. The correlation of digestibility 
tests with allergenicity potential is not absolute (Bøgh and Madsen, 2016; EFSA, 2017). Some 
food allergens are stable for up to 60 minutes in SGF, while non/low allergenic proteins are 
rapidly digested (Astwood et al., 1996; Fuchs and Astwood, 1996; Thomas et al., 2004b). 
However, some non-allergenic proteins may also be relatively stable to digestion, whilst some 
allergens may be rapidly degraded (Fu et al., 2002; Herman et al., 2007). Therefore, enzymatic 
degradation tests are recognized as not absolutely predictive. (Foster et al., 2013). In addition, 
the size of the remaining fragments after digestion that would be considered as being without 
allergenicity potential is not well defined.  The minimum size of peptides which might act as B-
cell receptor epitopes and cause IgE cross-linking is not clear, but require the presence of at 
least two epitopes which can only be accommodated in peptides greater than 9 amino acids in 
length (EFSA, 2017). 
The SGF test is limited in its capacity to replicate human digestion, as it does not represent all 
physiological conditions of the gastric digestion. In various cases, including early childhood or 
elderly age, during a meal or while taking antacid medication, the pH of the stomach increases 
above 4 and/or the gastric pepsin concentration and activity decrease (Bourlieu et al., 2014; 
Chen et al., 2008; Grassi et al., 2011; Minekus et al., 2014; Untersmayr et al., 2005). More 
physiologically relevant tests have recently been developed (Mills and DuPont, 2013). Static 
digestion models are available which consist of combinations of simulated gastrointestinal 
proteolysis processes, including a gastric phase, a duodenal phase, and sometimes an oral 
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phase (Mandalari et al., 2009; Minekus et al., 2014). A recent international consensus method 
described by Minekus et al. (2014) and later validated by three inter-laboratory trials using 
skimmed milk powder demonstrates the importance of applying standardized methods allowing 
data comparison and discussion across laboratories (Egger et al., 2016).  
Dynamic digestion models include physical processing and temporal changes in luminal 
conditions for getting closer to the in vivo digestion process (Björck, 2012; Mitea et al., 2008). 
These physiological models study the digestion of compounds of interest including allergens, 
the effect of food matrix, and the effect of food processing. However, they were not developed, 
nor evaluated, for their relevance in the prediction of protein allergenicity. Furthermore, they 
also demand considerably more resources. 
The interpretation of these enzymatic degradation assays must take into account that they do 
not provide a direct measure of allergenicity, but provide corroborative data on an endpoint 
associated with allergenicity (cross reactivity). Importantly, there has been little work on the 
applicability of these assays to proteins contained in a complex food matrix, rather than purified 
proteins. Such models could help understanding the possible effects of food matrix and/or food 
processing on the digestibility and allergenicity of the proteins.  
 
5.3 Impact of processing 
The physicochemical properties (solubility, stability, conformation, and matrix interaction) of a 
particular protein impact on how and to what extent the immune system might be exposed to 
allergenic polypeptides. For example, heat stability of novel proteins has been mentioned as an 
influencing factor in guidance documents (CODEX, 2009; EFSA, 2011). However, the effects of 
protein function/conformation loss on clinical allergenicity are not consistent: they can have no 
effect, may increase, or reduce the allergic reaction (Privalle et al., 2011). The respective 
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outcome depends on the allergen and allergen family, the sensitization profiles of the allergic 
patients, or the heating procedure used (Verhoeckx et al., 2015). Currently, assessment of the 
allergenicity potential for proteins after processing is not generally performed, and comparisons 
between differently processed allergens and different products are difficult to make. Processing 
may influence, but does not necessarily eliminate the allergenic potential of dietary proteins 
(e.g. baked egg vs raw egg) (Leonard et al., 2015). Heat stability tests of novel food proteins 
generally show a low correlation between protein stability to heat and potential to elicit 
reactions, and provide limited information as part of the allergenicity risk assessment of novel 
proteins. However, consideration of how food is processed and prepared for consumption is 
important when preparing material for testing in experimental studies to investigate hazard 
identification and characterization of new or modified proteins, and to determine the extent of 
exposure.  
6 In vivo centred investigations  
At present, in vivo models are the only methods able to to assess the hazard (and thus risks) 
due to de novo sensitization. However the current tests have several limitations, whether in 
animals or humans, to characterize tolerance vs allergenicity and further, the potency and dose 
of responses. Proper study design, including the appropriate choice of controls, test materials 
and subject selection should in theory provide a comprehensive allergenicity overview for new 
dietary proteins using in vivo methods (see Table 3).  
All in vivo studies, including animal studies and clinical trials, exist within an ethical framework 
which must be taken into account not only in the deployment of existing methods, but also in the 
development of new ones. An evaluation of the evidence generated in previous steps, as well 
as a complete toxicological evaluation of the test substance(s) is required prior to animal studies 
or clinical trials. 
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6.1 Animal models 
Animal models are widely used in research laboratories to study sensitization to food proteins, 
and are the only model in which de novo sensitization has been demonstrated, although their 
performance is strongly dependent on experimental design and conditions (choice of 
species/strain, route of exposure, adjuvants, etc). They are not generally used in the risk 
assessment of a new protein/new food, as they do not permit reliable characterisation of the 
hazard, and validated models do not exist. This potential use, but acknowledged limitation, is 
reflected in the guidelines for GM crops. CODEX (2009) states that animal models may be used 
as part of a risk assessment strategy as scientific knowledge and technology evolve. In 2010, 
an EFSA opinion concluded: “Animal models are in general considered not validated and 
inconclusive for the assessment of the sensitizing potential of a novel protein” (EFSA, 2010). A 
year later the EFSA GM-crop guideline opens for the possibility of using animal models stating 
that although “in vivo tests on animal models have not been validated so far for regulatory 
purposes, they may be considered useful to provide additional information e.g. on the potential 
of the newly expressed protein for de novo sensitization” (EFSA, 2011). In practice, a positive 
result may thus be able to assert a potential for allergenicity, but a negative one would not be 
able to exclude it.  
 
6.1.1 The continuing challenge of predicting a rare event in humans using a small number of 
experimental animals 
Food allergy is a prevalent disease but an allergic reaction to a single protein is a relatively rare 
event in humans when considering the number of known allergenic proteins in contrast with the 
total number of known proteins. The default response to a new dietary protein is to develop oral 
tolerance through hypo-responsiveness in order to protect the organism from producing a 
harmful response to an innocuous substance. Oral tolerance also causes hypo-responsiveness 
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to subsequent local or systemic exposure to the same protein or cross-reacting proteins (Kim 
and Surh, 2015; Kroghsbo et al., 2011). The greatest challenge in developing animal models is 
to avoid the default reaction “oral tolerance” in a way that preserves as much as possible of the 
normal physiology and protein chemistry so that it will predict sensitization in a meaningful way. 
One way to experimentally overcome oral tolerance is to circumvent the GI tract by dosing 
intraperitoneally (i.p) or subcutaneously (s.c.), but this has the disadvantage of potentially 
overestimating sensitization because the digestive tract is circumvented (Ladics et al., 2010). 
When using the oral route, it is important to bypass the oral cavity by dosing intragastrically (i.g.) 
as dosing in the mouth tends to induce oral tolerance (Madsen and Pilegaard, 2003). In mice, 
cholera toxin used as adjuvant enhances absorption through the gastrointestinal tract (GI) and 
also has a stimulating effect on the immune system (Frossard et al., 2015). The drawback of 
using an adjuvant is potentially overestimating sensitization. In Brown Norway rats, specific IgE 
can be induced by food allergens using i.g. dosing without adjuvant. The disadvantage of this 
model is the relatively low IgE response induced, decreasing the sensitivity and the possibility to 
study symptoms after challenge (Knippels and Penninks, 2003; Kroghsbo et al., 2014b). The 
advantage of the oral route is that the influence of the food matrix and processing methods 
(crude preparation, real food, purified protein) may be studied. The disadvantage is that oral 
dosing requires larger amounts of the test protein than i.p. or s.c. dosing (Kroghsbo et al., 
2014a).  
When using rodents one should be aware that there are strain differences in the ability to mount 
an IgE response to a specific protein (Ladics et al., 2010), just as there are differences between 
different human beings. This applies as much to the question of whether an immune response 
occurs, as to the issue of ranking different proteins when trying to characterize the hazard 
(Blaikie and Basketter, 1999). Diet is also a critical issue, and there is clear evidence of potential 
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epigenetic effects, insofar as the ability of a given generation to mount an allergic immune 
response is influenced by the parental diet and even that of earlier generations. To be able to 
induce a relevant immune response the animals need to be bred on a diet without the antigen or 
cross-reacting antigens for 2-3 generations as tolerance interferes with the response (Kroghsbo 
et al., 2011).  
6.1.2 Hazard characterisation  
Much of the effort when developing animal models for food allergy has been focused on the 
potential for a protein to sensitize i.e. induce a specific IgE response. Many foods are able to 
induce specific IgE and allergic symptoms in humans. Some of these cause allergic reactions in 
very few subjects although they contain storage proteins and are frequently eaten e.g. potato 
and maize (Informall). They are potentially hazardous but the risk connected to these foods is 
very small. Optimally, animal models should be able to predict not only if a food protein can 
induce specific IgE, but also its potency in doing so. There are several parameters for 
characterizing the allergenic potential of a food or protein, for instance: (i) the protein sensitizes 
many subjects when exposed, (ii) the symptoms elicited are frequently severe, (iii) the doses 
eliciting symptoms are low, and (iv), the protein sensitizes at a low dose. The first three 
parameters are difficult to study in any model, including animal models. Results may depend on 
the nature of the exposure (route, adjuvant, matrix, etc.), with either sensitization or tolerance as 
a possible outcome. 
Most allergenic proteins are present in native foods in relatively high concentrations (e.g. casein 
in milk, ovalbumin in egg, parvalbumin in fish, etc.), leading to high exposure of consumers 
under normal conditions of consumption. In theory, this exposure results in induction of 
tolerance, although if exposure is not high and/or frequent enough, or does not occur within an 
appropriate time-window it will lead to sensitization in predisposed individuals (Du Toit et al., 
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2015). Indeed, experience from animal models as well as some epidemiological evidence of 
non-food allergens shows that the dose-response for food allergens may not be linear 
(Custovic, 2015). Increasing the dose of allergenic protein does not necessarily increase the 
induction of IgE (Kroghsbo et al., 2014a). Data from animal models have also indicated that 
there may be an optimum dosage and frequency for sensitization (and a dose below which the 
immune system ignores the protein), probably depending on the specific allergen (Vinje et al., 
2009; Vinje et al., 2011), but more research is needed in this area. Recent studies of peanut 
allergy prophylaxis in high risk infants suggest that these observations from animal studies may 
also be true for human sensitization (Du Toit et al., 2015). In the absence of alternatives, some 
well-defined animal models have been used to address highly specific questions, such as, 
comparing the sensitizing capacity of related proteins (Kroghsbo et al., 2011) or investigating 
how modification of a particular food or protein influences sensitization (Kroghsbo, Rigby, et al., 
2014).  
6.1.3 Future for animal models in risk assessment  
There are still many unknowns regarding sensitization to food allergens in humans, including 
dose-response relationships and potency. There have been many attempts to develop 
predictive animal models for food allergy using different dosing routes with or without adjuvants 
and with or without multiple doses to include dose-response as a source of information (Bøgh et 
al., 2016; Ladics et al., 2010). The major challenge is to correctly rank potential novel food 
allergens as a function of potency, based on the potency rank order of known food allergens, a 
challenging task when it is difficult in any case to categorise proteins in this respect. Up to now 
no useful, reliable and validated animal model (or any model) that meets this criterion has been 
developed.  
6.2 Clinical approaches to allergenicity testing of new protein sources  
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While clinical studies are primarily considered in the context of cross-reactivity, circumstances 
exist where they can be used to investigate the sensitization potential of a protein. The 
framework in which the Human Repeat Insult Patch Test (HRIPT) is used to rule out the 
potential for skin sensitization (using low molecular weight allergens) in contact allergy, could 
also be appropriate for new protein sources. In that framework, the assay is set up with the 
hypothesis that a certain level of exposure to a chemical will not cause sensitization, (i.e. the 
exact opposite of the basis of animal tests). This same principle is the message of a 
sensitization and oral tolerance study to peanut performed in mice, which is more tailored 
toward the higher molecular weight allergens in food allergy (Strid et al., 2004).  
Clinically relevant allergy can result from cross-reactivity or de novo sensitization. It is important 
to realize that while many individuals can be sensitized to a dietary protein, only a proportion 
experience clinical symptoms upon re-exposure, and are therefore considered allergic to that 
protein (an allergen). Both CODEX and EFSA guidance indicate that if homology to known 
allergens, and/or pepsin resistance is observed, then immunological tests using human sera, 
such as specific IgE binding studies, are recommended. This type of test, similar to routine 
clinical diagnostic tests utilizing the detection and quantitation of specific IgE (e.g. by 
ImmunoCAP™), in general only indicates the presence or absence of sensitization to a known 
protein, but not clinical allergy. IgE antibody levels to some specific individual proteins (e.g. Ara 
h 2, Cor a 9 and 14) can predict the likelihood of a reaction on challenge (Klemans et al., 2013; 
Masthoff et al., 2013), but these results are specific for a particular (clinical) population and vary 
by study (Calvani et al., 2015). They also do not predict reaction severity.  
Before entering into any trial using human sera or designing a clinical trial it is very important to 
evaluate the existing information on the test material, the intended use and the food matrix. The 
selection of participants in a clinical study depends primarily on the hypothesis to be tested.  
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Subject selection 
To select appropriate individuals for allergenicity testing, it is important to realize that food 
allergic patients are very different from one to another. They usually are allergic to more than 
one food and with different specific IgE titers, different recognition patterns of specific allergens 
and varying degrees of severity of the allergy. Moreover, food allergy can be cross-reactive 
(with inhalant or food allergens) but not always. Food-allergic patients can be only plant food-
allergic, animal food-allergic or both. In addition a proportion of patients are only sensitized but 
not clinically allergic. In specific cases food allergic reactions only occur after exercise (e.g. in 
wheat dependent exercise induced allergy, WDEIA) (Scherf et al., 2016). 
Depending on the research question, one has to select the appropriate group of subjects, and 
do a systematic clinical and lab work-up to fully characterise the  (food) allergies of the patients. 
In individuals with known clinical allergy to a specific food, cross reactivity can occur when a 
novel protein has a high amino acid sequence homology to a known allergenic protein, epitope 
or component as is in the food causing the allergy (Verhoeckx et al., 2016). There are many 
examples of clinically relevant cross reacting proteins in the literature, such as Bet v 1, LTP, 
profilin and others (Hoffmann-Sommergruber and Mills, 2009; Werfel et al., 2015).  
People with a high risk of de novo sensitization to novel proteins are more difficult to identify. 
Individuals selected to investigate the de novo-sensitization to test materials should come from 
a group that is at high-risk for developing food allergies because of the presence of atopic 
symptoms or a family history of allergy. This can be either with a broad sensitization and/or 
allergy pattern or with more specified spectrum of sensitizations/allergies and the specific 
population needs to be decided based on the research question. As with cross-reactivity, other 
factors such as physical activity in food dependent exercise induced allergy might be taken into 
account.  
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Individuals can be exposed and become sensitised via other routes than the digestive tract. 
Therefore, individuals working in an occupational setting with respiratory or dermal exposure to 
the new protein or previous dermal exposure (e.g. in case the studied protein is already present 
as ingredient in cosmetic products) are a potentially at risk group which in assessments could 
provide valuable insights into de novo sensitization and subsequent reactions.  
 
6.2.1 In vitro investigations with ex-vivo materials from allergic individuals.  
IgE binding 
 IgE-binding studies should be conducted if a novel protein is closely phylogenetically related to 
a known allergen or if specific amino acid sequence homology has been shown with known 
allergens. Positive results in binding studies can be regarded as indication for a possible cross-
reactivity or co-sensitization with known allergens. This requires sera from clinically verified 
food-allergic individuals and has to be done in collaboration with experienced clinical partners. 
Serum must optimally be obtained from well-characterised, at-risk allergic patients who have a 
convincing history of allergic reactions to a particular allergenic food, with a positive 
ImmunoCAP™ ( >0.35 kU/L) and/or skin prick test (SPT), AND preferably a positive double-
blind placebo-controlled food challenge (DBPCFC) to the allergenic food. When DBPCFC is not 
possible, patients with sensitization above the 95% PPV level could be used or patients with a 
recent (within one year) reaction due to accidental exposure to a food allergen that could be 
clearly identified. 
Negative controls are needed for a proper serum screen of the novel protein. If results with 
serum from at-risk persons are ambiguous a broad panel of sera from individuals with different 
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allergy profiles can be used (i.e. pollen, plant, animal) and examined with different analytical 
methods (ELISA, RAST, immunoblot) (Verhoeckx et al., 2016).  
Functional basophil activation tests 
It is important to remember that IgE-binding in a serum screen does not automatically indicate 
clinically relevant allergy. In vitro functional IgE-binding options include the basophil activation 
test (BAT), which requires only 1 mL of blood from the at-risk individuals, no cell separation and 
measures the activation markers on the basophil surface (i.e. CD63 and CD203c) with flow 
cytometry after allergen stimulation (Chirumbolo et al., 2008). Previously, BAT has been shown 
to discriminate between allergic and non-reactive individuals sensitized to peanut (Santos et al., 
2014). However, van Erp et al. (2017) recently showed that due to spontaneous releasers and 
non-responders BAT is not more informative than component specific ImmunoCAP. The BAT 
has the advantage that denatured proteins extracted using stringent conditions (e.g. urea and 
SDS/DTT) can be investigated, which would not be possible (dermal irritation) in direct clinical 
testing (see below). More research is needed regarding the applicability of BAT, as a number of 
issues including nonspecific activations and release can occur. There is also a Rat Basophilic 
Leukaemia cells (RBL) assay available. However, strict serum requirements regarding 
specific/non-specific IgE ratios and nonspecific activation and release limit the widespread 
applicability of BAT and RBL tests for investigation of new proteins.  
6.2.2 Clinical testing options 
Skin prick testing (SPT)  
SPT is the least invasive first step in clinical testing. Protein extracts of the new protein source 
(in all processed forms) and of the single purified protein should be applied. Unfortunately, 
solvents usable in skin testing are limited by the need to remain within acceptable physiological 
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parameters (e.g. pH, irritancy, general safety – microbiological and chemical, etc.). Insoluble or 
difficult to solubilize proteins can only be tested in vitro or ex or in vivo in, for example, basophil 
activation testing or prick-to-prick methods. For prick-to-prick applications the test protein is 
transferred from the source directly to the skin without previous extraction. The prick-to-prick 
method lacks standardization, but can be very informative (Bolhaar et al., 2005; Henzgen et al., 
2008). SPT can be performed before the oral challenge (as below) to get information on 
clinically relevant sensitization in the study participants to (parts of) the tested product. 
Oral challenge  
IgE-mediated food allergy is the elicitation of allergic symptoms upon ingestion in sensitized 
persons. Oral challenge is the only test to demonstrate unequivocally the presence of true food 
allergy. The “gold standard” for confirming food allergy is a DBPCFC with the tested food protein 
or food product. The double blinding allows both patient and clinic staff to evaluate signs and 
symptoms as objectively as possible.  
Oral human immunogenicity studies  
 
Longer term ingestion studies with the protein or protein source of interest (e.g. Crevel et al. 
(2007)) can also be informative to identify potential immunogenicity and therefore the possibility 
of allergenicity. These studies should be of sufficient duration to allow any antibody response to 
become manifest. As discussed earlier, such studies can only be conducted once the general 
safety of the test material has been ascertained and following an assessment of the weight of 
evidence in accordance with guidelines described earlier. In this context their use is similar to 
the Human Repeat Insult Patch Test to confirm the absence of sensitising potential in materials 
applied to the skin. However, it must be noted that the appropriate number of subjects should be 
included to ensure proper predictive power and this would likely be more than the 50-200 
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individuals used in the Human Repeat Insult Patch Test due to the relative low expected 
frequency of food allergy.  
In summary, with careful selection of appropriate subject and control groups, based on the study 
design, clinical evaluation is a powerful tool to predict allergenicity of new and existing proteins. 
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7 Discussion  
Food allergy is a relatively rare event in humans as the default reaction to a dietary protein is to 
develop oral tolerance. Adaptive immune responses, such as allergy, consist of two phases: 
sensitization and elicitation, which must be analysed separately. Quantitative approaches to 
assess the risk posed by substances eliciting reactions in already sensitized individuals are 
proving very successful (Allen et al., 2014; Crevel et al., 2014). However, dose responses in 
relation to sensitization look to be non-linear, probably because exposure may lead to either 
tolerance or sensitization. To complicate matters further the relationship between sensitization 
and elicitation is complex. The manner in which the population is exposed to new proteins also 
impacts on the risk of potential sensitization and allergenicity.  
Guidelines developed so far focus on hazard analysis, and on mainly structural characteristics 
for for the potential to elicit an allergic reaction, in already sensitised individuals. The available 
tools analyse for properties of known allergens, and function best for cross-reactivity. None of 
the available methods have been formally validated for their predictive abilities, and there are 
only few standardised methodologies available (in comparison to OECD testing protocols for 
toxicological testing of chemicals). The current weight-of-evidence approach seems supported 
empirically and successfully for decision-making, to the extent that no cases of human allergic 
responses have been reported to any foods derived from approved agricultural biotechnology 
products (Ladics, 2008). Current approaches that have required assessing safety through a 
weight-of-evidence approach to approve GM crop commercialization appear to be well suited to 
protecting consumers. One key piece of evidence in terms of food allergy is that consumers in 
countries extensively cultivating and producing foods from GM crops (e.g., the US) have levels 
of food allergy indistinguishable from other world areas with similar socio-economic profiles, but 
with negligible consumption of foods from GM crops (e.g., the EU) (James, 2015; Nwaru et al., 
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2014; Sicherer, 2011). Exposure to these products has been low in comparison to that expected 
for proteins used for nutritional reasons. Novel foods intended as protein sources may thus pose 
different challenges, in that complex mixes of proteins are expected, and exposure scenarios 
will be very different. 
Current focus is on applying existing tools and tests to assess the risks due to cross-
reactivity/co-sensitization but little is available for a strategy to identify and characterise with 
reasonable certainty the risks arising from de novo sensitization. No single test is available (or 
expected in the near future) for predicting or for characterising the de novo sensitization 
potencies of new proteins. The only tests that can identify if a protein will induce specific IgE is 
in vivo models in animals or humans, although as discussed in this document, there are many 
limitations to characterise the potency and dose responses , and uncertainties to characterise 
tolerance vs allergenicity. In addition, there are ethical aspects to consider. As yet, no in silico or 
in vitro approach can be used to identify the potential of a protein to sensitise, and subsequently 
elicit a clinical reaction. An overall mechanistic model (or adverse outcome pathway, AOP) for 
food allergy does not yet exist, Human allergic responses are complex, and while extensive 
research has been conducted, predictive models remain elusive. Arguably, the (very) limited 
ability to predict sensitization restricts the development and use of novel protein sources, which 
is crucial to make our future food supply more sustainable. There is a need for a 
comprehensive, systematic testing and assessment strategy to identify and characterise the 
risks associated with allergic reactions due to de novo sensitization to specific proteins, which 
incorporates relevant aspects of exposure, intrinsic protein properties and matrix/processing 
effects. New potential allergenic hazards are currently managed through avoiding exposure. Not 
authorizing the introduction of an identified new allergen into the marketplace, or by identifying 
an indication for allergenicity early in development (which may lead to cancelling the project) 
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avoids exposure of the whole population. Labelling will alert consumers with existing 
sensitivities to the presence of a potential hazard (e.g. rapeseed protein isolate and individuals 
with existing mustard seed allergies). However it does nothing to mitigate the public health 
impact of a protein with high food sensitizing potency. In the absence of methodologies to 
determine sensitization potential and potency, a post-launch monitoring exercise may be 
considered to provide an early warning of any undue allergenicity developing after introduction 
of a novel food into the market and thereby permit the initiation of risk management measures. 
Possibilities and limitations for such resource intensive post-launch monitoring in the context of 
novel foods and unintended health effects has been critically discussed (Hepburn et al., 2008) 
and the special case of allergenicity has been reviewed (Wal et al., 2003). 
Development of a coherent risk assessment strategy would benefit greatly from a clear 
definition of criteria for distinguishing between proteins of high and low allergenicity (i.e. ability to 
induce IgE, potency to induce IgE, expected prevalence of IgE-sensitization, expected 
prevalence of allergy, expected exposure, expected eliciting potency, expected frequency of 
reactions, expected frequency of severe reactions). Appropriate tests could then be applied, or 
developed as needed, to investigate the relevant protein characteristics. The COST Action 
network (ImpARAS, www.imparas.eu) has recently started to discuss these criteria from first 
principles and will continue with the broader subject of improving strategies for allergen risk 
assessment throughout 2016-2018/9. 
For any chosen approach it will be important to demonstrate that the methodologies are able to 
distinguish between allergens of different potency and rank them appropriately. The current 
general lack of systematic data to rank existing, known allergenic proteins impairs the 
necessary work to validate any of potentially alternative methodologies. This applies to both the 
potential to sensitize and subsequently elicit reactions, although good progress has been made 
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with regard to the risk assessment of elicitation by known allergens. As scientific knowledge 
progresses, it should be possible to improve the methodologies used in allergenicity risk 
assessment, e.g. new possibilities due to the development of bioinformatics tools, and relevant 
in vitro biological tests. It will be vital to identify those approaches, methods and technologies on 
which future research efforts should be focussed, taking into account their current performance, 
but also the scope for their evolution into predictive approaches.  
Although knowledge of historical use and exposure is useful to focus assessments for potential 
cross-reactivity, it is of little value when investigating completely novel proteins and their 
inherent risk for de novo sensitization. The consideration of exposure levels is a key element for 
assessing consumer risk, and clinical studies could have an important role for assessing the 
allergenic potential of new dietary proteins. However, we should not wait until we have fully 
defined all the clinical adverse outcome pathways (AOPs) related to food allergy, but rather 
select a battery of tests which can distinguish between low and high allergenic proteins, defined 
on the basis of accepted criteria for allergenicity (see above). The battery of currently available 
tests could be run using a panel of selected known strong, moderate, weak and (virtually) non-
allergenic proteins to help to identify the most efficient testing strategy for allergenicity 
differentiation. A better understanding of AOPs could guide the development of better in vitro 
and in vivo allergenicity testing methods. Therefore, it is important to leave room for flexibility 
and improvement of methodologies within any regulation or guidance, as our progression of 
knowledge will aid with the development and improvement of tests and tools. 
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Table 1.  Key elements for allergenicity assessment of new foods from existing guidance documents 
Element GM Foods : transgenic proteins Non-GM Foods (single proteins, extracts, whole foods) 
Background  History of exposure and safety of gene product and 
sources 
Comprehensive literature review 
Food composition, particularly its protein(s), its source, the production 
process, and available experimental and human allergenicity data.  
Case reports of allergic reactions and/or allergenicity studies (in vitro, in 
animals, in humans)   
Protein analysis In silico amino acid sequence comparisons to known 
allergens 
Physico-chemical properties e.g. resistance to pepsin 
degradation in vitro 
Protein Content ( ACNFP 2011)  (Total , specific) 
Degree of amino acid sequence homology with known allergens 
Immunological tests (e.g. Western blotting with human sera) 
Molecular weight of the potentially allergenic protein, heat stability, 
sensitivity to pH, digestibility by gastrointestinal proteases 
Human testing Specific IgE binding studies using well-characterized sera 
from individuals allergic to the identified source or skin-
prick testing with relevant subjects  
Detection of specific IgE antibodies 
Skin prick testing  
Double blind placebo controlled food challenge studies 
Other possibilities Animal models, in vitro biological assays  (EFSA 2014b) 
 
Inclusion of the expression of endogenous allergens into 
the comparative compositional analysis of the GM plant 
and its appropriate comparator (EFSA 2010, 2011, 2017) 
 
Post-launch monitoring 
Demonstration (characterisation, manufacturing process, literature, 
human data, animal data, in vitro data ) that derivatives of foods 
considered as allergens are unlikely to trigger adverse reactions and are 
exempt from labelling (EFSA, 2013).   
 
Post-launch monitoring 
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Table 2. Information relating to source organisms/whole foods and single proteins (or Description of history of safe use) 
Whole foods/ Source Organism Single Proteins 
Element Considerations  Element Consideration 
Characterisation 
and Identity 
Does it belong to a food group known to be 
allergenic? 
Are some varieties more/less allergenic than others? 
Is the allergen known? 
Source organism Can a history of safe use be described? 
Details of use Is the food cooked or eaten raw? Are certain parts of 
the plant avoided? 
Is the food an extract (e.g. oil, flour? Is protein 
present as consumed?) 
What is the impact of processing? 
Protein 
familiarity 
Sequence homologies to other proteins within the 
same protein family OR with other protein families OR 
known allergens? 
Is the protein well conserved (sequence & structure & 
function)? 
Human 
Exposure 
Pattern 
Timing and frequency of consumption?  
Geographical/cultural/environmental influences? 
Staple food or minor ingredient? 
Dietary 
Exposure 
Is the protein abundant in nature – is there significant 
consumption of the protein (or highly related 
proteins)?  
Known Health 
Effects 
What is the level of scientific evidence for elicitating 
allergic reactions? Severity? 
Anecdotal reports or confirmed by clinical 
investigation? 
Processing Impact of digestive enzymes and/or temperature on 
protein stability. 
Is the protein easily processed;  no undesired products 
generated 
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Table 3    Considerations in designing anin vitro/in-vivo clinical testing plan 
Parameter Considerations 
Test material Exposure from its intended commercial food use must be a pre-requisite for considering clinical tests.   The safety of the test 
material (viral, bacteriological, toxicological) has to be assessed prior to clinical testing.  
Test solutions used in SPT should comply with requirements for medicinal products under observation of GCP standards. The 
intended use of the protein or protein preparation (with multiple proteins present) in food, and expected processing steps for its 
final commercial use must be considered  when selecting the form of protein to be tested: extracts, purified protein or processed 
forms. Preferably, all possible processing methods should be taken into account in the assessment. Potential differences in 
allergenicity of processed forms can be tested in vitro and possibly by SPT. 
Food matrix 
effects 
 
Dilution of protein and matrix fat content can change the test outcome and possibly lead to incorrect interpretation of results 
(Mackie et al 2012; Schulten et al 2012) in in vitro, SPT, and in double blind placebo controlled studies.  
Prevention of possible reactions to matrix proteins could be achieved by introducing as few additional allergens as possible into the 
challenge test material and by making sure that the tested individual can consume all ingredients without problems. 
Selection of 
individuals 
 
Selection of the subjects based on expected cross-reactivity, co-sensitization or de-novo sensitization (see text).  
Individuals selected for allergy testing of a novel or modified protein should come from a group at high-risk for developing food 
allergies. 
Inclusion of control groups of atopic patients, without co-sensitization to homologous proteins, and preferably healthy individuals to 
ensure the relevance of any observed reaction. 
Study design  
 
Clear description of the outcome parameter and the number of individuals needed to make a sound statistical basis.  
The outcome can be sensitization, allergy, or severity of allergy. If one outcome is regarded to be more important than another, this 
could result in the selection of individuals from a group that is most valuable for answering that particular question. 
The IgE reactivity profile measured for an individual will be compared to the same person’s IgE reactivity profile to a reference food 
or similar proteins (reference proteins) to which a confirmed allergy exists (subjects in the high risk group). The IgE reactivity will be 
compared to the reactivity of the non-allergic control group.  
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Highlights 
The potential of current methods to identify and characterize the risk of sensitization or 
cross-reactivity for IgE-mediated allergy is reviewed. 
Existing methods are capable of assessing the allergenic potential of new proteins for cross 
reactivity. 
Currently there are limited options to assess the hazard and potential risks of new proteins 
due to de novo sensitization. 
Development of a coherent risk assessment strategy would benefit from a clear definition of 
criteria for distinguishing between proteins of high and low allergenicity.  
From these criteria, more suitable tests can be developed to distinguish between proteins of 
high and low allergenicity. 
